Table 1 Characteristics of cancer patients who received therapeutic single-port 3-dimensional endoscopic-assisted breast surgery (S-P 3D EABS)
ALL (N = 131) | S-P 3D E-NSM (N = 117) | S-P 3D E-BCS (N = 14) | |
|---|---|---|---|
Age, years, N (%) | |||
< 40 | 13 (9.9) | 13 (11.1) | 0 |
≧ 40, < 60 | 81 (61.8) | 72 (61.5) | 9 (64.3) |
≧ 60 | 37 (28.2) | 32 (27.3) | 5 (35.7) |
Mean ± SD | 53.2 ± 10.7 | 52 ± 10.8 | 55.8 ± 9.9 |
BMI (kg/m2), N (%) | |||
< 18 | 2 (1.6) | 2 (1.7) | 0 |
18–24 | 70 (53.4) | 62 (53) | 8 (57.1) |
> 24 | 59 (45) | 53 (45.3) | 6 (42.9) |
Location, N (%) | |||
Right | 74 (56.5) | 66 (56.4) | 8 (57.1) |
Left | 57 (43.5) | 51 (43.6) | 6 (42.9) |
Sonographic tumor size, cm, mean ± SD | 2.5 ± 1.2 | 2.6 ± 1.2 | 2.2 ± 1 |
Neoadjuvant, N (%) | |||
Yes | 35 (26.7) | 33 (28.2) | 2 (14.3) |
No | 96 (73.3) | 84 (71.8) | 12 (85.7) |
Axillary surgery, N (%) (NA = 4) | |||
SLNB | 100 (78.7) | 87 (77) | 13 (92.9) |
SLNB + ALND | 25 (19.7) | 24 (21.2) | 1 (7.1) |
ALND | 2 (1.6) | 2 (1.8) | 0 |
Reconstruction, N (%) | |||
No reconstruction | 51 (38.9) | 39 (33.3) | 12 (85.8) |
Gel implant | 71 (54.2) | 71 (60.7) | 0 |
TRAM flap | 7 (5.3) | 7 (6) | 0 |
LD flap | 1 (0.8) | 0 | 1 (7.1) |
Omental flap | 1 (0.8) | 0 | 1 (7.1) |
Pathologic tumor size, cm, mean ± SD | 2.7 ± 2.4 | 2.9 ± 2.5 | 2.1 ± 1.1 |
Histology, N (%) | |||
DCIS | 33 (25.2) | 32 (27.4) | 1 (7.1) |
IDC | 79 (60.3) | 68 (58.1) | 11 (78.6) |
ILC | 8 (6.1) | 7 (6) | 1 (7.1) |
Othersa | 11 (8.4) | 10 (8.5) | 1 (7.1) |
Pathological N status, N (%) | |||
N0 | 94 (71.8) | 82 (70.1) | 12 (85.7) |
N1 | 27 (20.6) | 25 (21.4) | 2 (14.3) |
N2 | 7 (5.3) | 7 (6) | 0 |
N3 | 3 (2.3) | 3 (2.5) | 0 |
Pathological staging, N (%) | |||
0/pCR | 38 (29) | 36 (30.8) | 2 (14.3) |
I | 28 (21.4) | 21 (17.9) | 7 (50) |
II | 50 (38.2) | 45 (38.5) | 5 (35.7) |
III | 15 (11.4) | 15 (12.8) | 0 |
ER, N (%) (NA = 12) | |||
Positive | 95 (79.8) | 84 (79.2) | 11 (84.6) |
Negative | 24 (20.2) | 22 (20.8) | 2 (15.4) |
PR, N (%) (NA = 14) | |||
Positive | 75 (64.1) | 67 (64.4) | 8 (61.5) |
Negative | 42 (35.9) | 37 (35.6) | 5 (38.5) |
HER-2, N (%) (NA = 30) | |||
Positive | 18 (17.8) | 16 (18.2) | 2 (15.4) |
Negative | 83 (82.2) | 72 (81.8) | 11 (84.5) |
Ki-67, N (%) (NA = 40) | |||
≦ 14 | 41 (45) | 35 (44.9) | 6 (46.2) |
> 14 | 50 (55) | 43 (55.1) | 7 (53.8) |
Endocrine therapy, N (%) (yes) | 86 (65.7) | 76 (65) | 10 (71.4) |
Chemotherapy, N (%) (yes) | 63 (48.1) | 58 (49.6) | 5 (35.7) |
Radiotherapy, N (%) (yes) | 50 (38.2) | 38 (32.5) | 12 (85.7) |